系统性硬化症胃部病变:谱系、挑战与系统综述的启示
该研究按PRISMA指南对MEDLINE、EMBASE和Web of Science进行系统检索,纳入37篇探讨系统性硬化症胃部表现(胃动力障碍、GAVE、黏膜异常、幽门螺杆菌)的文献。结果显示胃排空延迟为18-64%、GAVE患病率0-22.3%、幽门螺杆菌感染率10-78%,但客观指标与患者报告结局关联不一致,胃部特异性死亡率数据有限。作者呼吁标准化诊断工具、验证患者报告结局并开展纵向研究。
要点
- 系统性硬化症胃动力障碍常见,胃排空延迟达18-64%,胃电节律过缓为12-70%。
- GAVE患病率0-22.3%,与抗拓扑异构酶I抗体负相关、与抗RNA聚合酶III抗体关联不一。
- 幽门螺杆菌感染率10-78%,活检或呼气试验检出率低于血清学,胃部特异性死亡率数据有限。
核心结论
- 系统性硬化症胃部病变临床常见但被低估,需标准化诊断、验证患者报告结局及纵向研究以明确疾病负担和优化治疗。
研究设计与样本
- 系统综述按PRISMA指南开展并在PROSPERO注册,系统检索MEDLINE、EMBASE和Web of Science(2024年9月)。
- 共123篇全文文章,37篇符合纳入标准,研究涉及系统性硬化症胃动力障碍、GAVE、黏膜异常和/或幽门螺杆菌。
主要发现
- 胃动力障碍频繁,胃排空延迟见于18-64%的患者,胃电节律过缓见于12-70%的患者。
- GAVE患病率为0-22.3%,与抗拓扑异构酶I抗体呈负相关,与抗RNA聚合酶III抗体关联不一。
- 黏膜异常(如胃炎、溃疡、癌症)常见但定义不一致;幽门螺杆菌感染率10-78%,活检或呼气试验检出率低于血清学。
- 客观发现与患者报告结局之间的关联不一致且研究不足,胃部特异性死亡率数据有限。
关键数值与推荐
- 推荐标准化诊断方法,包括闪烁显像、呼气试验和胃电图。
- 推荐使用经过验证的患者报告结局(PROs)并开展纵向研究,以明确疾病负担、优化筛查和指导靶向治疗。
临床怎么用
- 临床应关注系统性硬化症患者的胃部症状,对胃动力障碍、GAVE和幽门螺杆菌感染进行系统评估。
- 诊断幽门螺杆菌时需注意活检或呼气试验检出率低于血清学,应结合临床选择合适检测方法。
- 建议采用标准化诊断工具和患者报告结局评估胃部病变,并开展纵向随访以指导治疗。
局限性
- 纳入研究对黏膜异常等定义不一致,客观发现与患者报告结局关联不一致且研究不足。
- 胃部特异性死亡率数据有限,证据 gaps 需纵向研究进一步明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gastric complications in systemic sclerosis (SSc) are common, clinically diverse, and often overlooked, despite their profound impact on patient quality of life. This review synthesizes current evidence on prevalence, clinical relevance, and diagnostic strategies, while identifying key gaps and proposing priorities to advance care and research. METHODS: A systematic review was conducted per PRISMA guidelines and registered with PROSPERO. MEDLINE, EMBASE, and Web of Science were systematically searched (September 2024). Included studies addressed gastric manifestations in SSc, such as dysmotility, gastric antral vascular ectasia (GAVE), mucosal abnormalities, and/or Helicobacter pylori, and reported on prevalence, clinical impact, or diagnostic approaches. RESULTS: Of 123 full-text articles, 37 met our specified inclusion criteria. Gastric dysmotility was frequent, with delayed emptying in 18-64 % and bradygastria in 12-70 %. GAVE prevalence ranged from 0 to 22.3 % and was negatively associated with anti-topoisomerase-I and variably associated with anti-RNA polymerase III antibodies. Mucosal abnormalities (e.g., gastritis, ulcers, cancer) were common but inconsistently defined. Helicobacter pylori prevalence varied widely (10-78 %), with lower detection via biopsy or breath testing than serology. Associations between objective findings and patient-reported outcomes (PROs) were inconsistent and underexplored; data on gastric-specific mortality were limited. CONCLUSION: Gastric disease in SSc is underrecognized, yet clinically significant. Progress necessitates standardized diagnostics (scintigraphy, breath tests, electrogastrography), validated patient-reported outcomes (PROs), and longitudinal studies to better define disease burden, optimize screening, and guide targeted therapies that improve outcomes and quality of life in SSc.
引用
- Anderton RM, Zhu A, Ayla A, et al. Gastric disease in systemic sclerosis: Spectrum, challenges, and insights from a systematic literature review. Semin Arthritis Rheum. 2026. PMID: 41687407. doi:10.1016/j.semarthrit.2026.152944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。